<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02157415</url>
  </required_header>
  <id_info>
    <org_study_id>OPM-G-H-1101</org_study_id>
    <secondary_id>Cl V-1 3-03-010344</secondary_id>
    <nct_id>NCT02157415</nct_id>
  </id_info>
  <brief_title>Prospective Cohort Study on Tolerability &amp; Safety of Uro-Tainer® Polihexanide 0.02%</brief_title>
  <official_title>Prospective Cohort Study on the Tolerability and Safety of Uro-Tainer® Polihexanide 0.02% in Long-term Indwelling Catheterized Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Ltd. Centre of Excellence Infection Control</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B. Braun Ltd. Centre of Excellence Infection Control</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is the first clinical study aimed at assessing the safety and tolerability of UT-P as&#xD;
      routine rinsing and bacterial decolonization solution device for urinary catheters. The study&#xD;
      will be conducted in hospitalized adult patients who had an urethral or suprapubic catheter&#xD;
      in place for longer than two consecutive weeks and who are able to provide written consent.&#xD;
&#xD;
      This is an open-label prospective observational cohort study. No comparative control group is&#xD;
      planned as no other preventing infection solution is commercially available at this time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to assess the tolerability and safety of Uro-Tainer®&#xD;
      Polihexadine 0.02% intended as routine rinsing and bacterial decolonization of urinary&#xD;
      catheters in long-term catheterized patients. After each instillation patients will be&#xD;
      assessed for vital signs, skin reactions and other symptoms suggesting intolerance or&#xD;
      sensitivity and/or allergic reaction. In addition, pain will be assessed in the first 5&#xD;
      patients and any other patients with sustained pain sensation in the bladder.&#xD;
&#xD;
      Catheters will be rinsed by gravity feed with 100ml solution of UT-P 0.02% once a day for a&#xD;
      maximum of 5 instillations. A minimum interval of 24 hours must be guaranteed for the&#xD;
      enrolment of the first 5 patients and their first irrigation with the investigational&#xD;
      product.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    After consultation with a medical expert the Notified Body confirmed premature termination of&#xD;
    the study.&#xD;
  </why_stopped>
  <start_date type="Actual">August 2013</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to assess the tolerability of Uro-Tainer® Polihexanide 0.02%</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 4, Day 5</time_frame>
    <description>Change in Visual Analogue Scale (VAS) Score for patients with sustained pain sensation in the bladder Bladder spasms Blood pressure (change in SBP ≥ 40 mmHg is a discontinuation criterion, see 7.4.3) Heart rate Change in tympanic temperature Urine Dipstick (LEU) Occurrence of Flushing Occurrence of Sweating</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety of Uro-Tainer® Polihexanide 0.02% in long-term catheterized patients</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 4, Day 5</time_frame>
    <description>Adverse Events&#xD;
Urticaria&#xD;
Exanthema&#xD;
Any other signs and symptoms associated with allergic reactions</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Complications; Catheter, Urinary (Indwelling Catheter) (Suprapubic)</condition>
  <arm_group>
    <arm_group_label>Long-term catherized patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Uro-Tainer Polihexanide 0.02% 100ml rinsing solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Uro-Tainer Polihexanide 0.02%</intervention_name>
    <description>Catheters will be rinsed by gravity feed with 100ml solution of UT-P 0.02% once a day for a maximum of 5 instillations.</description>
    <arm_group_label>Long-term catherized patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a sustained pain sensation in the bladder (for the first five patients).&#xD;
&#xD;
          -  Patients staying as inpatients with long-term (&gt; 2 weeks) urethral or suprapubic&#xD;
             catheters.&#xD;
&#xD;
               -  Age &gt; 18 years&#xD;
&#xD;
               -  Ability to read, write and speak German or French&#xD;
&#xD;
               -  Women of child bearing potential must test negative on standard urine pregnancy&#xD;
                  test two weeks prior to the start of the study and must agree to practice&#xD;
                  appropriate contraceptive methods until the end of the study (e.g. oral&#xD;
                  contraceptive, IUD, intra-muscular contraceptive, abstinence).&#xD;
&#xD;
               -  Provision of voluntary consent to participate in the study, following a full&#xD;
                  explanation of the nature and purpose of the study, by signing the informed&#xD;
                  consent approved by the cantonal Ethics Committee (IEC) prior to all evaluations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic UTI&#xD;
&#xD;
          -  Hematuria&#xD;
&#xD;
          -  Fever (tympanic temperature &gt; 38.5°C)&#xD;
&#xD;
          -  Surgical intervention to genito-urinary tract in the last 6 months&#xD;
&#xD;
          -  Patients receiving any other concurrent catheter irrigation&#xD;
&#xD;
          -  Known allergy or sensitivity to any of the ingredients in Uro-Tainer® Polihexanide&#xD;
             0.02%&#xD;
&#xD;
          -  Known allergy or sensitivity to chlorhexidine&#xD;
&#xD;
          -  Pregnancy or Lactation&#xD;
&#xD;
          -  Simultaneous participation in another interventional trial&#xD;
&#xD;
          -  Administration of any other catheter irrigation 1 week prior to study&#xD;
&#xD;
          -  Administration of any of the following medications 4 weeks prior to study entry,&#xD;
             unless they have been used at a stable regimen : antibiotics, antipyretics,&#xD;
             antihistamines, medications susceptible to cause an autonomic response or to mask an&#xD;
             allergic reaction.&#xD;
&#xD;
          -  For the first five patients: impaired pain sensation in the bladder for the first five&#xD;
             patients: Administration of any antipyretics and analgesic.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jürgen Pannek, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Schweizer Paraplegikerzentrum Nottwil</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitair Ziekenhuis</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken-Beelitz GmbH</name>
      <address>
        <city>Beelitz Heilstätten</city>
        <zip>14547</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schweizerisches Paraplegikerzentrum</name>
      <address>
        <city>Basel</city>
        <state>BS</state>
        <zip>4056</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schweizer Paraplegikerzentrum</name>
      <address>
        <city>Nottwil</city>
        <state>LU</state>
        <zip>6207</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rehaklinik</name>
      <address>
        <city>Valens</city>
        <state>SG</state>
        <zip>7317</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>May 9, 2014</study_first_submitted>
  <study_first_submitted_qc>June 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2014</study_first_posted>
  <last_update_submitted>July 31, 2018</last_update_submitted>
  <last_update_submitted_qc>July 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polihexanide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

